Payment overview · 2025
General Payments
$1,897.75
115 reported records · 30 companies
Healthcare provider profile · identity verified
Anne E Campbell
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · UPLAND, IN · NPI 1528559697
Verified facts
What the public records show
CMS Open Payments records show Anne E Campbell received $1,897.75 in general payments during 2025 across 115 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $389.91 | 20.6% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $364.31 | 19.2% | 30 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $135.79 | 7.2% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.53 | 4.3% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $65.26 | 3.4% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.00 | 3.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.34 | 3.1% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$55.94 | 3.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.47 | 2.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $50.37 | 2.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.07 | 2.4% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $45.17 | 2.4% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.39 | 2.3% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.44 | 2.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.86 | 2.1% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $36.48 | 1.9% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $34.70 | 1.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.85 | 1.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.95 | 1.5% | 4 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $27.65 | 1.5% | 1 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $25.78 | 1.4% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $23.45 | 1.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22.71 | 1.2% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $22.49 | 1.2% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.62 | 1.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.62 | 1.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.30 | 0.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.70 | 0.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.25 | 0.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.35 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,897.75 | 115 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $358.50 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $221.15 | 18 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $113.94 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $110.54 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $105.86 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $89.77 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $82.55 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.49 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $65.26 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $65.00 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $60.35 | 4 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $55.94 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $53.25 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $50.37 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $45.17 | 3 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $41.44 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.11 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.86 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.40 | 2 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.85 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $32.62 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $32.62 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.93 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.93 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.16 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.16 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.95 | 4 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $23.45 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.32 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.54 | 2 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $12.92 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 46 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 114 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 36 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 126 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
151 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
114 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
126 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
80 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 789 | 218 |
| Levothyroxine Sodium | Levothyroxine Sodium | 503 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 474 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 406 | 112 |
| Ezetimibe | Ezetimibe | 378 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 367 | 97 |
| Lisinopril | Lisinopril | 324 | 88 |
| Losartan Potassium | Losartan Potassium | 305 | 83 |
| Metformin Hcl | Metformin Hcl | 300 | 92 |
| Alendronate Sodium | Alendronate Sodium | 244 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 62 |
| Omeprazole | Omeprazole | 221 | 60 |
| Gabapentin | Gabapentin | 157 | 36 |
| Sertraline Hcl | Sertraline Hcl | 155 | 39 |
| Synthroid | Levothyroxine Sodium | 151 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 39 |
| Mounjaro | Tirzepatide | 126 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 37 |
| Farxiga | Dapagliflozin Propanediol | 114 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 42 |
| Meloxicam | Meloxicam | 100 | 30 |
| Valsartan | Valsartan | 96 | 23 |
| Allopurinol | Allopurinol | 94 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 87 | 76 |
| Carvedilol | Carvedilol | 84 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 24 |
| Trulicity | Dulaglutide | 80 | 18 |
| Montelukast Sodium | Montelukast Sodium | 78 | 27 |
| Trazodone Hcl | Trazodone Hcl | 73 | 17 |
| Potassium Chloride | Potassium Chloride | 72 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 20 |
| Simvastatin | Simvastatin | 64 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 21 |
| Alprazolam | Alprazolam | 60 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 17 |
| Metformin Hcl Er | Metformin Hcl | 60 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 16 |
| Buspirone Hcl | Buspirone Hcl | 54 | 16 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 53 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 13 |
| Furosemide | Furosemide | 51 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 43 |
| Prednisone | Prednisone | 48 | 40 |
| Spironolactone | Spironolactone | 48 | 13 |
| Tramadol Hcl | Tramadol Hcl | 47 | 15 |
| Eliquis | Apixaban | 46 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 46 | 13 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 15 |
| Jardiance | Empagliflozin | 36 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 22 | 15 |
| Glimepiride | Glimepiride | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Glipizide | Glipizide | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,897.75 · 115 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, EDARBI, ELIQUIS, FANAPT, FARXIGA, GEMTESA, IBSRELA, INJECTAFER, INTELLIS ADAPTIVESTIM, JARDIANCE, Jornay PM, Kerendia, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OFEV, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SAPIEN 3 Ultra RESILIA, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, UNITHROID, VOQUEZNA, VRAYLAR, Veozah, WAKIX, WATCHMAN FLX, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error